Warning Letter — Alchymars ICM SM Private Limited
The FDA issued a warning letter to Alchymars ICM SM Private Limited following an inspection by the Center for Drug Evaluation and Research (CDER).
This notice affects Alchymars ICM SM Private Limited, its pharmaceutical manufacturing operations, and regulatory/quality personnel responsible for CGMP oversight at their facilities.
A formal warning letter from CDER signifies that the facility has documented violations of Current Good Manufacturing Practice (CGMP). This may lead to the withholding of new drug approvals or the imposition of import alerts, which could restrict the company's ability to distribute products in the U.S. market until corrective actions are verified and the violations are resolved.
Quality teams should review internal audit programs to ensure CGMP compliance at international manufacturing sites and prepare for potential disruptions in the supply chain if import alerts are issued. QA should verify that all documentation and manufacturing processes align with CDER expectations for drug substance or product integrity.
FDA Warning Letter issued to: Alchymars ICM SM Private Limited. 05/21/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alchymars-icm-sm-private-limited-724429-05212026
Open in openFDA / FDA.gov